411 related articles for article (PubMed ID: 27370607)
21. Regulation of microRNA expression by hepatocyte growth factor in human head and neck squamous cell carcinoma.
Susuki D; Kimura S; Naganuma S; Tsuchiyama K; Tanaka T; Kitamura N; Fujieda S; Itoh H
Cancer Sci; 2011 Dec; 102(12):2164-71. PubMed ID: 21899661
[TBL] [Abstract][Full Text] [Related]
22. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
23. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling.
Rajamoorthi A; Shrivastava S; Steele R; Nerurkar P; Gonzalez JG; Crawford S; Varvares M; Ray RB
PLoS One; 2013; 8(10):e78006. PubMed ID: 24147107
[TBL] [Abstract][Full Text] [Related]
24. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
25. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
26. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
27. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N
J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691
[TBL] [Abstract][Full Text] [Related]
28. New promising molecular targets in head and neck squamous cell carcinoma.
Bauman JE; Michel LS; Chung CH
Curr Opin Oncol; 2012 May; 24(3):235-42. PubMed ID: 22327839
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B.
Zeng Q; Chen S; You Z; Yang F; Carey TE; Saims D; Wang CY
J Biol Chem; 2002 Jul; 277(28):25203-8. PubMed ID: 11994287
[TBL] [Abstract][Full Text] [Related]
30. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
García-Vilas JA; Medina MÁ
World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
32. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
33. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.
Kumar D; Kandl C; Hamilton CD; Shnayder Y; Tsue TT; Kakarala K; Ledgerwood L; Sun XS; Huang HJ; Girod D; Thomas SM
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1133-9. PubMed ID: 26540318
[TBL] [Abstract][Full Text] [Related]
34. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
Gambella M; Palumbo A; Rocci A
Expert Rev Mol Diagn; 2015; 15(7):881-93. PubMed ID: 25967746
[TBL] [Abstract][Full Text] [Related]
35. Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Xu Y; Zhou J; Carey TE; McHugh JB; Voorhees JJ; Fisher GJ
Neoplasia; 2012 Nov; 14(11):1015-22. PubMed ID: 23226095
[TBL] [Abstract][Full Text] [Related]
36. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
37. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
38. Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis.
Sun S; Wang Z
Int J Cancer; 2011 Nov; 129(10):2337-48. PubMed ID: 21225626
[TBL] [Abstract][Full Text] [Related]
39. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.
Ausoni S; Boscolo-Rizzo P; Singh B; Da Mosto MC; Spinato G; Tirelli G; Spinato R; Azzarello G
Cancer Metastasis Rev; 2016 Sep; 35(3):413-26. PubMed ID: 27194534
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
